ConductVision Organoid Monitor
Tumor organoids, monitored 24/7
In a pilot, ConductVision counts your tumor organoids and follows each one's growth, growth arrest and regrowth, from images taken every 5 to 15 minutes.
24/7 monitoring
What a pilot records for each tumor organoid
ConductVision records each measure for every visible organoid, keyed by plate, well, organoid ID and time.
| Measure | What it shows | How often |
|---|---|---|
| Every organoid | ||
| Area | The projected area of each organoid, with its longest and shortest diameters | Every 5 to 15 minutes |
| Growth rate | How fast each organoid grows or shrinks, per hour and per day | Every 5 to 15 minutes |
| Shape | How round, long or irregular each outline is | Every 5 to 15 minutes |
| Movement | How far and how fast each organoid moves, where organoids are free to move | Every 5 to 15 minutes |
| Fusion | Two organoids joining into one, with both parent IDs kept | Each time it happens |
| Fragmentation | Organoids splitting or shedding pieces, each piece keeping its parent ID | Each time it happens |
| Structural collapse | A sudden loss of area, roundness or boundary, with a clip of the change | Each time it happens |
| Tumor organoids | ||
| Count | How many visible organoids each well holds, as they form, fuse and break up | Every 5 to 15 minutes |
| Treatment response | Growth arrest, shrinkage and response latency after a treatment, normalized to each organoid's own baseline and your controls | Every 5 to 15 minutes |
| Regression and regrowth | Regression, regrowth and recurrent growth after a first response | Every 5 to 15 minutes |
| Protrusions and gross invasion | Large protrusions, and gross invasion into the surrounding gel, where the camera resolves them | Every 5 to 15 minutes |
| Differences between organoids | The share of organoids growing, stable and shrinking in each well, beside the well average | Every 5 to 15 minutes |
When a fusion, fragmentation or structural collapse begins, the camera images that well every minute until the change ends. Fragmentation and structural collapse describe what the camera sees in each organoid's outline, not whether its cells are alive.
Beyond the camera
What needs higher magnification or a dye
- Individual cells
- Cell division (mitosis)
- Single cells invading the gel
- Molecular markers
Evidence
What published studies found in tumor organoids
Other research groups measured these in microscope images of patient-derived organoids.
Count and area without dyes
OrBITS monitored patient-derived organoids over time at all stages of growth from brightfield images alone, without a fluorescent dye.1 Its organoid counts and areas correlated strongly with Hoechst nuclear staining over a broad range of sizes.1
Growth rate
Deben and colleagues, whose OrBITS study included two genetically validated pancreatic cancer organoid lines, advise a growth rate-based metric to measure organoid drug responses more accurately and consistently.1
Stalled or shrinking organoids
To tell cytostatic from cytotoxic responses, Deben and colleagues added a fluorescent dye that marks damaged cells to their brightfield imaging.1 A pilot uses no dyes, so it reports when an organoid stalls, shrinks, fragments or collapses, but cannot say whether the drug stopped its growth or killed it.
Fusion
In OrBITS time-lapses, organoid counts dropped over time as organoids merged or fused.1 A pilot gives each fused organoid a new ID that records both parents, so the count stays traceable.
Structure scored by an observer
Yu and colleagues imaged rectal cancer organoids every 3 days for 15 days after X-ray doses, and a trained observer scored each structure as complete or disrupted.2 The score judged the integrity of each structure, independent of organoid size.2
Label-free drug responses
Larsen and colleagues optimized a pan-cancer tumor organoid platform on cultures from over 1,000 patients.3 Their neural network measured tumor organoids' drug responses from label-free light-microscopy images, across solid cancers.3
Each organoid's response
Spiller and colleagues tracked how individual patient-derived tumor organoids responded to drugs, in brightfield images taken at several time points without vital dyes.4
Camera specification
The cameras a pilot uses
Around the clock
- A full stack of focal planes for every well, every 5 to 15 minutes
Image
- 2 µm or less per pixel
Light
- Brightfield LED light, with no dyes or labels
Incubator
- Inside your incubator, or in a chamber beside it that keeps the same conditions
References
- Deben C, De La Hoz EC, Compte ML, et al. (2023). OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening. Cellular Oncology.
- Yu H, Lin C, Chen F, et al. (2025). Dose response test of patient-derived cancer organoids to irradiation. Frontiers in Oncology.
- Larsen BM, Kannan M, Langer LF, et al. (2021). A pan-cancer organoid platform for precision medicine. Cell Reports.
- Spiller ER, Ung N, Kim S, et al. (2021). Imaging-Based Machine Learning Analysis of Patient-Derived Tumor Organoid Drug Response. Frontiers in Oncology.
Plan a tumor organoid pilot
Tell us about your tumor organoids, your plates, your treatments and the response you want timed.
